Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanofi Consumer Healthcare India has the GF Score of 21, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Sanofi Consumer Healthcare India
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Sanofi Consumer Healthcare India GF Score Related Terms
NSE:SANOFICONR vs LLY, JNJ, ABBV: GF Score Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's GF Score distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's GF Score falls into.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a GF Score of 21 as of Jul. 21, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Sanofi Consumer Healthcare India and its competitors. This is 11% above median its historical median of 19.00. Over the past decade, Sanofi Consumer Healthcare India's GF Score has ranged from 4.00 to 27.00.
Is Sanofi Consumer Healthcare India's GF Score too high?
Sanofi Consumer Healthcare India's current GF Score of 21 is 11% above median its 10-year median of 19.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 27.00. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's GF Score compare to LLY and JNJ?
Sanofi Consumer Healthcare India's GF Score of 21 can be compared against companies in the Drug Manufacturers industry. Historically, Sanofi Consumer Healthcare India's own GF Score has ranged from 4.00 to 27.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Sanofi Consumer Healthcare India and its competitors. Sanofi Consumer Healthcare India's current GF Score is 21, which is 11% above median its own 10-year median of 19.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current GF Score of 21. The current GF Score is 21, which is 11% above median its 10-year median of 19.00. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current GF Score is 21 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Business Description
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score
Get the complete analysis for NSE:SANOFICONR
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
